Kiora Licenses KIO-401 From Senju in Deal With Up to $168.5 Million in Milestones
Kiora Pharmaceuticals entered an exclusive license agreement with Senju Pharmaceutical to develop and commercialize KIO-401 for ophthalmology uses in specified territories. Kiora will pay $3.5 million upfront; further payment terms are truncated.
Story updates
11:28:45 AM UTC
SquawkNews
KIORA PHARMACEUTICALS - TO PAY SENJU LOW TEEN MILLIONS UPON TECHNOLOGY TRANSFER COMPLETION - SEC FIL
Kiora Pharmaceuticals entered into an exclusive license agreement with Senju Pharmaceutical to develop and commercialize KIO-401, a late-stage oral calpain inhibitor, for ophthalmology uses in specified territories. Kiora will pay $3.5 million upfront, a low-teens-million-dollar payment upon techno…